Department of Health Care Management, Baskent University, Ankara, Turkey.
Rheumatol Int. 2010 Mar;30(5):637-41. doi: 10.1007/s00296-009-1040-2. Epub 2009 Jul 7.
Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution (SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as euro 2,669.14 patient/year. Outpatient costs were found to be euro 240.40. Routine tests during the year were calculated as euro 98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was euro 87.76. euro 2,238 was determined as being paid per year for medication alone (including anti-TNF) and euro 4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies.
本研究旨在从土耳其的报销机构(社会保障机构)角度确定类风湿关节炎(RA)的成本。为了分析直接成本,我们遵循了国际 RA 临床指南。数据来自医院账单、社会保障机构价格清单和卫生部药品价格清单。RA 患者的直接成本估计为每年 2669.14 欧元。门诊费用为 240.40 欧元。当年的常规检查费用为 98.85 欧元。每年有 10%的患者住院,其中 0.62%的患者接受了关节置换术和/或其他干预措施。住院费用为 87.76 欧元。每年仅用于药物(包括抗 TNF)的费用就达 2238 欧元,每年还花费 4 欧元用于辅助材料。我们的数据显示 RA 对社会造成了巨大的经济影响。我们希望 RA 研究的成本将有助于报销机构的定价实践。